The role of bisoprolol in modern cardiology | Medycyna Faktow (J EBM)

PDF (Język Polski)

Published: Oct 20, 2026

DOI: https://doi.org/10.24292/01.MF.0226.12

Keywords:

bisoprolol, cardioselectivity, heart failure with reduced ejection fraction, coronary artery disease, cardiac arrhythmias

Olaf Zabłocki

I Katedra i Klinika Kardiologii, Warszawski Uniwersytet Medyczny

Krzysztof Ozierański

I Katedra i Klinika Kardiologii, Warszawski Uniwersytet Medyczny

Abstract

Numerous guidelines from the European Society of Cardiology position β-blockers as fundamentally important in the treatment of patients with heart failure with reduced ejection fraction, cardiac arrhythmias (including atrial fibrillation), chronic coronary syndrome, post-myocardial infarction with left ventricular dysfunction, and hypertension with concomitant indications. Bisoprolol, a long-acting cardioselective β-blocker, combines a predictable negative chronotropic effect, anti-ischemic activity, a favourable pharmacokinetic profile, and the possibility of once-daily dosing. Clinical data support its importance in controlling heart rate, improving prognosis in stable heart failure with reduced ejection fraction, and treating patients at high cardiovascular risk.

How to Cite

Zabłocki, O., & Ozierański, K. (2026). The role of bisoprolol in modern cardiology. Medycyna Faktow (J EBM), 19(2(71), 222-227. https://doi.org/10.24292/01.MF.0226.12

Issue

Vol 19 No 2(71) (2026)

Section

Articles

Copyright by Medical Education. All rights reserved.

References

1. Van Gelder IC, Rienstra M, Bunting KV et al. 2024 ESC Guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2024; 45(36): 3314-414. http://doi.org/10.1093/eurheartj/ehae176.
2. Marti HP, Pavía López AA, Schwartzmann P. Safety and tolerability of β-blockers: importance of cardioselectivity. Curr Med Res Opin. 2024; 40(supl. 1): 55-62. http://doi.org/10.1080/03007995.2024.2317433.
3. Bennett M, Chang CL, Tatley M et al. The safety of cardioselective β1-blockers in asthma: literature review and search of global pharmacovigilance safety reports. ERJ Open Res. 2021; 7(1): 00801-2020. http://doi.org/10.1183/23120541.00801-2020.
4. Taddei S, Tsabedze N, Tan RS. β-blockers are not all the same: pharmacologic similarities and differences, potential combinations and clinical implications. Curr Med Res Opin. 2024; 40(supl. 1): 15-23. http://doi.org/10.1080/03007995.2024.2318058.
5. Leopold G. Balanced pharmacokinetics and metabolism of bisoprolol. J Cardiovasc Pharmacol. 1986; 8(Suppl. 11): S16-20. http://doi.org/10.1097/00005344-198511001-00003.
6. Tucker WD, Sankar P, Theetha Kariyanna P. Selective Beta-1 Blockers. 2023 Jan 30. In: StatPearls. StatPearls Publishing ; Treasure Island (FL) 2026.
7. Yamashita T, Inoue H. Heart rate-reducing effects of bisoprolol in Japanese patients with chronic atrial fibrillation: results of the MAIN-AF study. J Cardiol. 2013; 62(1): 50-7. http://doi.org/10.1016/j.jjcc.2013.02.010.
8. Van Gelder IC, Groenveld HF, Crijns HJ et al.; RACE II Investigators. Lenient versus strict rate control in patients with atrial fibrillation. N Engl J Med. 2010; 362(15): 1363-73. http://doi.org/10.1056/NEJMoa1001337.
9. Kotecha D, Bunting KV, Gill SK et al; Rate Control Therapy Evaluation in Permanent Atrial Fibrillation (RATE-AF) Team. Effect of Digoxin vs Bisoprolol for Heart Rate Control in Atrial Fibrillation on Patient-Reported Quality of Life: The RATE-AF Randomized Clinical Trial. JAMA. 2020; 324(24): 2497-508. http://doi.org/10.1001/jama.2020.23138.
10. Zeppenfeld K, Tfelt-Hansen J, de Riva M et al.; ESC Scientific Document Group. 2022 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. Eur Heart J. 2022; 43(40): 3997-4126. http://doi.org/10.1093/eurheartj/ehac262.
11. A randomized trial of beta-blockade in heart failure. The Cardiac Insufficiency Bisoprolol Study (CIBIS). CIBIS Investigators and Committees. Circulation. 1994; 90(4): 1765-73. http://doi.org/10.1161/01.cir.90.4.1765.
12. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet. 1999; 353(9146): 9-13.
13. Leizorovicz A, Lechat P, Cucherat M et al. Bisoprolol for the treatment of chronic heart failure: a meta-analysis on individual data of two placebo-controlled studies – CIBIS and CIBIS II. Cardiac Insufficiency Bisoprolol Study. Am Heart J. 2002; 143(2): 301-7. http://doi.org/10.1067/mhj.2002.120768.
14. Frishman WH. Multifactorial actions of beta-adrenergic blocking drugs in ischemic heart disease: current concepts. Circulation. 1983; 67(6 Pt 2): I11-8.
15. Cruickshank JM. Are we misunderstanding beta-blockers. Int J Cardiol. 2007; 120(1): 10-27. http://doi.org/10.1016/j.ijcard.2007.01.069.
16. Byrne RA, Rossello X, Coughlan JJ et al.; ESC Scientific Document Group. 2023 ESC Guidelines for the management of acute coronary syndromes. Eur Heart J. 2023; 44(38): 3720-826. http://doi.org/10.1093/eurheartj/ehad191.
17. Munkhaugen J, Kristensen AMD, Halvorsen S et al.; BETAMI–DANBLOCK Investigators. Beta-Blockers after Myocardial Infarction in Patients without Heart Failure. N Engl J Med. 2025; 393(19): 1901-11. http://doi.org/10.1056/NEJMoa2505985.
18. Rossello X, Prescott EIB, Kristensen AMD et al. β blockers after myocardial infarction with mildly reduced ejection fraction: an individual patient data meta-analysis of randomised controlled trials. Lancet. 2025; 406(10508): 1128-37. http://doi.org/10.1016/S0140-6736(25)01592-2.
19. Kristensen AMD, Rossello X, Atar D et al.; Beta-Blocker Trialists’ Collaboration Study Group. Beta-Blockers after Myocardial Infarction with Normal Ejection Fraction. N Engl J Med. 2026; 394(6): 540-50. http://doi.org/10.1056/NEJMoa2512686.
20. Shu de F, Dong BR, Lin XF et al. Long-term beta blockers for stable angina: systematic review and meta-analysis. Eur J Prev Cardiol. 2012; 19(3): 330-41. http://doi.org/10.1177/1741826711409325.
21. bbJouven X, Empana JP, Schwartz PJ et al. Heart-rate profile during exercise as a predictor of sudden death. N Engl J Med. 2005; 352(19): 1951-8. http://doi.org/10.1056/NEJMoa043012.
22. Sorbets E, Steg PG, Young R et al.; CLARIFY investigators. β-blockers, calcium antagonists, and mortality in stable coronary artery disease: an international cohort study. Eur Heart J. 2019; 40(18): 1399-407. http://doi.org/10.1093/eurheartj/ehy811.
23. Ford TJ, Stanley B, Good R et al. Stratified Medical Therapy Using Invasive Coronary Function Testing in Angina: The CorMicA Trial. J Am Coll Cardiol. 2018; 72(23 Pt A): 2841-55. http://doi.org/10.1016/j.jacc.2018.09.006.
24. Cegłowska U, Burzyńska M, Prejbisz A et al. Incidence and prevalence of registered hypertension in Poland. Pol Arch Intern Med. 2024; 134(6): 16746. http://doi.org/10.20452/pamw.16746.
25. Symonides B, Jędrusik P, Artyszuk L et al. Different diagnostic criteria significantly affect the rates of hypertension in 18-year-old high school students. Arch Med Sci. 2010; 6(5): 689-94. http://doi.org/10.5114/aoms.2010.17082.
26. Botros SM, Hussein AM, Elserafy AS. Effect of different beta blockers on penile vascular velocities in hypertensive males. The Egyptian Journal of Radiology and Nuclear Medicine. 2015; 342: 749-54. http://doi.org/10.1016/j.ejrnm.2015.04.004.
27. Broekman CP, Haensel SM, Van de Ven LL et al. Bisoprolol and hypertension: effects on sexual functioning in men. J Sex Marital Ther. 1992; 18(4): 325-31. http://doi.org/10.1080/00926239208412857.
28. Meattini I, Becherini C, Martella F et al. Cardioprotection in patients with anthracycline-treated breast cancer: final analysis from the 2 × 2 randomized, placebo-controlled, double-blind SAFE trial. ESMO Open. 2025; 10(6): 105116. http://doi.org/10.1016/j.esmoop.2025.105116.

Most read articles by the same author(s)

Krzysztof Ozierański , Paweł Balsam , Marcin Grabowski , Perindopril in patients with myocardial infarction ? experience of the Warsaw center , Cardiology in Practice: Vol 11 No 2 (2017)
Krzysztof Ozierański, Agnieszka Kapłon-Cieślicka, The importance of the optimal dose of acetylsalicylic acid in prevention of cardiovascular events , Medycyna Faktow (J EBM): Vol 16 No 2(59) (2023)
Emil Brociek, Krzysztof Ozierański, Latest data regarding properties and clinical use of rosuvastatin , Medycyna Faktow (J EBM): Vol 16 No 3(60) (2023)
Krzysztof Ozierański, Emil Brociek, What does a cardiologist want you to know about sitagliptin? , Medycyna Faktow (J EBM): Vol 16 No 3(60) (2023)
Krzysztof Ozierański, Robert Rupiński , Robert Małecki , Febuxostat is an effective and safe alternative to the treatment of gout. Perspectives of cardiologist, rheumatologist and nephrologist , Medycyna Faktow (J EBM): Vol 16 No 4(61) (2023)
Aleksandra Skwarek, Krzysztof Ozierański, The use of tadalafil in erectile dysfunction in patients with cardiovascular disease , Medycyna Faktow (J EBM): Vol 17 No 2(63) (2024)
Aleksandra Skwarek, Krzysztof Ozierański, Role of triple combination therapy in the treatment of hypertension , Medycyna Faktow (J EBM): Vol 17 No 4(65) (2024)
Aleksandra Skwarek, Krzysztof Ozierański, Safety of using etoricoxib in cardiac patients taking direct oral anticoagulants and beyond , Medycyna Faktow (J EBM): Vol 17 No 4(65) (2024)
Aleksandra Skwarek, Krzysztof Ozierański, Dabigatran - an effective drug with proven efficacy and a high safety profile , Medycyna Faktow (J EBM): Vol 17 No 4(65) (2024)
Aleksandra Skwarek, Krzysztof Ozierański, Combined therapy with candesartan and amlodipine in the treatment of hypertension in a young obese patient , Medycyna Faktow (J EBM): Vol 17 No 4(65) (2024)

1 2 > >>